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Summary
Objective: We have previously shown (Hunziker and Rosenberg, J Bone Joint Surg 1996;78A:721–33) that synovial cells can be induced to
migrate into partial-thickness articular cartilage defects, therein to proliferate and subsequently to deposit a scar-like tissue. We now wished
to ascertain whether these synovial cells could be stimulated to transform into chondrocytes, and thus to lay down cartilage tissue, by the
timely introduction of a differentiation factor.
Design: Partial-thickness defects were created in the knee-joint cartilage of adult miniature pigs. These were then filled with a fibrin matrix
containing a free chemotactic/mitogenic factor and a liposome-encapsulated chondrogenic differentiation one. Tissue was analyzed
(immuno)histochemically at 2, 6 and 12 months.
Results: Defects became filled with cartilage-like tissue which registered positive for all major cartilage-matrix components; it remained
compositionally stable throughout the entire follow-up period.
Conclusion: Although still requiring considerable refinement, our one-step, growth-factor-based treatment strategy has the basic potential
to promote intrinsic healing of partial-thickness articular cartilage defects, thus obviating the need for transplanting cells or tissue.
© 2001 OsteoArthritis Research Society International
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The appearance of discrete structural lesions within the
substance of mature articular cartilage tissue represents
one of the earliest overt signs of osteoarthritis (OA). That
such lesions fail to heal spontaneously1—and conse-
quently undergo inexorable enlargement with time—
accounts for the progressive nature of OA and for its
development into the debilitating condition that it ultimately
becomes.2–4 This intrinsic incapacity of articular cartilage
lesions to undergo spontaneous repair has been variously
interpreted. The most popular conception is that such
lesions, being walled off from the underlying bone-marrow
and blood-vascular spaces, are not accessible to these
sources of potential repair cells.5–9 However, we have
recently shown that cells from the synovial membrane
and subsynovial space can be locally stimulated to migrate
into the defect void.1,10 When appropriate measures are
taken to furnish the lesion with a space-filling matrix
containing the necessary chemotactic/mitotic factor, these
mesenchymal-like cells can be induced to populate it and
subsequently to lay down a primitive type of scar tissue.
This tissue endures, but fails to transform into cartilage.1
The need for introducing a tissue differentiation factor
into this system thus became evident. Transforming
growth factor-1 (TGF-1) represents one of the most
suitable candidates, since it is well known to induce the22formation of cartilage tissue.11–16 However, this substance
needs to be applied at a relatively high concentration to
be effective in its differentiation capacity. And since
several authors17,18 have shown that the free injection (or
infusion) of TGF-1 into the joint cavity precipitates
severe adverse effects, such as inflammatory joint dis-
ease, cartilage destruction and osteophyte formation,
great care must be exercised in its use. From these as
well as from our own studies,1 it has become evident that
this agent must be introduced directly into the defect void
and its sphere of influence confined to this site. Moreover,
the actual time of its application (or release) needs to be
well coordinated with the processes set in train by the
chemotactic/mitogenic factor, such that the necessary sig-
nal for remodeling does not come before the synovial
cells have laid down their mesenchymal-like tissue. It
was the aim of the present study to test whether this
end could be achieved by incorporating liposome-
encapsulated TGF-1, together with the free chemotactic/
mitogenic factor, into the space-filling matrix.
Histological, histochemical and immunohistochemical
analyses were undertaken to evaluate the nature of the
tissue formed during the course of 1 year, and measures
taken to assess its compositional stability and integration
with vicinal native cartilage.Received 20 July 1999; accepted 21 April 2000.
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EXPERIMENTAL ANIMALS, SURGERY, TREATMENT PROTOCOLS
Forty-seven mature Goettingen miniature pigs (2–4
years of age) were utilized for this investigation. They were
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hydrochloride) in combination with Halothan® (2-bromo-2-
chloro-1,1,1-trifluoraethane) and nitrous oxide (by intuba-
tion). Parapatellar medial arthrotomies were performed
simultaneously on both knee joints. Following exposure of
the femoral groove and the medial femoral condyle, super-
ficial defects were created using a custom-built planing
instrument (Rolf Haenggi-Engineering AG, Grenchen,
Switzerland).1,10,19 One proximal and one distal defect
were created on each facet of the patellar groove of the
femur and another on the medial femoral condyle (i.e. a
total of five defects per knee joint, each of which was
0.5 mm in depth, 0.5 mm in width and 8–10 mm in
length).
Defects in the 20 experimental animals (see Group I in
Table I) were dried and then filled with an aqueous solution
of chondroitinase AC (1 unit/ml) to remove cartilage matrix
glycosaminoglycans (proteoglycans) along the lesion sur-
face, thereby exposing the underlying collagenous net-
work. This step was undertaken to facilitate adherence of
the applied matrix to the defect walls,19,20 with the ultimate
aim of improving the structural integration between repairand native tissue. The enzyme solution was removed by
blotting with a sterile sponge after 4–5 min, the defect being
then thoroughly rinsed with physiological sodium chloride
solution and again blotted dry. Fibrinogen solution (19 mg/
ml of 0.15 M Tris-buffered saline) containing free (4 ng/ml)
and liposome-encapsulated (600 ng/ml) TGF-1, was then
deposited to bulging point within the void of each lesion,
approximately 2–4 l being required for this purpose.
Approximately 0.5–1 l of a thrombin solution (1 unit/ml of
0.15 M Tris-buffered saline) was then applied to the surface
of the fibrinogen solution, through which it permeated and
promoted polymerization and clotting in situ. The final
concentrations of fibrinogen and thrombin were estimated
to lie within ±25% of the original ones.
Defects in the other 27 animals served as controls;
details of their treatment are summarized in Table I.
The wounds were closed and animals permitted free
joint movement immediately after recovery from the oper-
ation. At the end of the follow-up period (2, 4, 6 or 12
months; see Table I), miniature pigs were again anesthe-
tized and then killed by administering an overdose of
potassium chloride to induce cardiac arrest.Table I
Experimental and control groups set up
Groups Treatment Number of
miniature pigs
Follow-up
period
Group I (experimental) Chondroitinase AC
Fibrin matrix 8 2 months
Free TGF-1 (4 ng/ml) 6 6 months
Liposome-encapsulated TGF-1 (600 ng/ml) 6 12 months
Group II (control) Untreated 2 2 months
2 6 months
2 12 months
Group III (control) Chondroitinase AC
Free TGF-1 (4 ng/ml)
Fibrin matrix
Empty liposomes 2 2 months
Group IV (control) Chondroitinase AC
Fibrin matrix 4 2 months
Group V (control) Chondroitinase AC
Gelatine matrix
Free TGF-1 (4 ng/ml)
Liposome-encapsulated TGF-1 (600 ng/ml) 2 2 months
Group VI (control) Chondroitinase AC
Gelatine/fibrin-copolymer matrix
Free TGF-11 (4 ng/ml)
Liposome-encapsulated TGF-1 (600 ng/ml) 4 2 months
Group VII (control) Chondroitinase AC
Fibrin matrix
Free IGF-1 (40 ng/ml)
Liposome-encapsulated TGF-1 (600 ng/ml) 2 2 months
Group VIII (control) Chondroitinase AC
Fibrin matrix
Free bFGF (10 ng/ml)
Liposome-encapsulated TGF-1 (600 ng/ml) 2 2months
Group IX (control) Chondroitinase AC
Fibrin matrix
Liposome-encapsulated TGF-1 (600 ng/ml) 2 2 months
Group X (control) Chondroitinase AC
Miniature-pig-derived fibrin matrix
Free TGF-1 (4 ng/ml)
Liposome-encapsulated TGF-1 (600 ng/ml) 3 2 months
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Fibrinogen was purified from the blood of either young
adult cows or Goettingen miniature pigs according to the
procedure described by Mosher et al.21 Purified fibrinogen
solutions were employed at a final concentration of 19 mg/
ml of 0.15 M Tris-buffered saline. Fibrinogen poly-
merization was induced by the addition of bovine thrombin,
the commercial product (10 units/ml) being diluted 1:10
immediately prior to use. A gelatine matrix (160 mg/ml of
Tris-buffered saline) and a gelatine/fibrin copolymer were
also prepared, the latter being generated by the addition of
160 mg of gelatine powder to 1 ml of the purified fibrinogen
solution described above.
Purified, freeze-dried TGF-1 (of porcine platelet
origin) was dissolved, according to the manufacturer’s
specifications (in 4 mM sterile hydrochloric acid containing
0.1% bovine serum albumin), immediately prior to use,
and employed either in free suspension at 4 ng/ml, or in a
liposome-encapsulated form. TGF-1 was encapsulated
within liposomes according to the standard procedure
described by Kim et al.22 Liposomes were prepared by the
evaporation of organic solvents from chloroform-ether
spherules suspended in water. Each spherule contained
numerous water droplets holding the solute to be trapped
upon solvent evaporation. The incorporation rate was esti-
mated (using I125-labeled TGF-1) to be 75%. Liposome
particles were utilized at a final concentration for TGF-1 of
600 ng/ml of fibrinogen solution. The retention rates of free
and liposome-encapsulated TGF-1 by fibrin matrices were
also monitored over a period of 25 days at 37°C in vitro
using I125-labeled TGF-1. The daily release rate of
liposome-encapsulated TGF-1 was steady at 2–3%, 73%
of this agent being still present within the fibrin matrix after
10 days; by the end of the 25th day, 47% of the liposome-
encapsulated TGF-1 had been retained. In contrast, the
rate of loss of non-encapsulated TGF-1 was fairly high
during the first few days of monitoring (between 15 and
20%), decreasing steadily thereafter to lower levels. By the
end of the 25th day, only 12% of the free agent had been
retained by the fibrin matrix (unpublished data).
Free insulin-like growth factor (IGF-1) and free basic
fibroblast growth factor (bFGF) were dissolved in 0.15 M
Tris-buffered saline to yield final concentrations of 40 and
10 ng/ml, respectively.TISSUE ANALYSIS
For routine histological and morphometrical analyses
using the light microscope, one large tissue block was
prepared from either the femoral groove or condyle; it
contained all of the lesions created in the relevant region.
Thick sections derived from each of the defects were
assessed. One tissue block from one animal per time point
was subjected to immunohistochemical analysis.
The degree of cell and tissue differentiation was quanti-
fied using three randomly-selected sections derived from a
series of eight to twelve along the entire defect length.
Tissue was defined as being ‘differentiated and cartilage-
like’ if cells exhibited a chondrocyte-like phenotype
(rounded form; surrounded by a lacuna) and if the matrix
manifested a cartilage-like organization. Areas in which
cells remained spindle-like (mesenchymal) and in which
the matrix remained predominantly fibrous in nature were
classified as being ‘non-differentiated’; intermediate states
of tissue differentiation were assigned to this latter cat-
egory. In all sections analyzed, the percentage of the area
transformed to cartilage-like tissue was estimated in steps
of 25% [i.e. less than 25%, between 26 and 50%, between
51 and 75% and more than 75% (see Table II)].
The staining intensity of the repaired cartilage matrix was
used as an index of its proteoglycan content. It was graded
semi-quantitatively by a blinded observer from 0 (purely
fibrous matrix) to + + + (intensity equivalent to that mani-
fested by normal native cartilage matrix). The number of
defects analyzed was the same as that used to estimate
tissue-transformation processes (see above).TISSUE PROCESSING
Distal femurs were removed immediately after the death
of animals and, unless otherwise specified (cf. immuno-
histochemical analyses), sawed into three pieces (medial
condyle; upper and lower halves of patellar groove) using
an Exakt® diamond saw. Tissue blocks were chemically
fixed for light microscopic analysis in a solution containing
glutaraldehyde and formaldehyde, both at a concentration
of 2.5% in 0.1 M sodium cacodylate buffer (pH 7.4), for 4–6
days at ambient temperature. They were then dehydrated
in a graded series of increasing ethanol concentration and
embedded in methyl methacrylate. Serial cuts through
blocks were produced perpendicular to the defect axis
using a Leco® diamond saw (Leco Corporation, St. Joseph,
U.S.A.). They were then glued onto polished plexiglas
object holders, milled to a thickness of approximately
80–150 m with a Reichert Polycut E apparatus (Reichert-
Jung, Nussloch, Germany), polished and surface-stained
with McNeil’s Tetrachrome/Toluidine Blue 0/basic Fuchsine.For analyses in the polarization microscope (Olympus
Vanox AH2), a selection of tissue cuts (80–120 m in
thickness) was prepared.
For immunohistochemical analyses, 1.3-mm-thick tissue
slices were prepared from native material using a diamond
saw. These were then mounted on a specimen holder using
Tissue Tek® and frozen with carbon dioxide. 20-m-thick
cryosections were produced in a Linde-cryostat using a
Jung stainless steel microtome. Sections were air-dried
and maintained in a frozen condition at −30°C until
required for immunostaining.
Immunostaining with horseradish-peroxidase-labeled
antibodies was carried out according to standard proto-
cols.23 For positive controls, normal articular cartilage tis-
sue (neighboring the defect site) was utilized. Negative
controls were prepared by applying antibodies against
artificial epitopes (a polyclonal anti-dansyl antibody and a
monoclonal antibody against chrome-pure epitopes). Anti-
bodies against collagen types I and II, the hyaluronic-acid-
binding region of proteoglycans, cartilage oligomeric matrix
protein and epitopes along glycosaminoglycan chains were
employed to characterize the repair tissue.
Prior to the immunostaining procedure, cryosections
were fixed in cold acetone, washed, treated with 1%
hydrogen peroxide (in methanol), again washed, incubated
with chondroitinase AC (40 milliunits/ml) for 60 min,
washed, and then exposed to 1% bovine serum albumin
(in 0.05 M Tris-phosphate buffer) for 30 min. After further
rinsing, the primary antibody was then applied at dilutions
of 1:50 and 1:200. After incubation for 1 h at ambient
temperature, sections were washed and then treated with
the peroxidase-labeled secondary antibodies (1:50 and
1:200) for 45 min.23
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The following materials and chemicals were used in this
study: acetone (Merck, Darmstadt, Germany); antibodies:
chrome-pure monoclonal antibody (Roche Co., Basel,
Switzerland), monoclonal antibodies against collagen types
I and II (Hybridoma Bank, Iowa, U.S.A.), polyclonal anti-
dansyl-antibody (gift from Dr D. Aeschlimann, Cardiff,
Wales) polyclonal antibody against the hyaluronic-
acid-binding region of proteoglycans (gift from Dr Dick
Heinegard, Lund, Sweden), polyclonal antibody against
cartilage oligomeric matrix protein (gift from Dr Mats
Paulsson, Cologne, Germany), monoclonal antibodies
(3B3 and 9-A-2) against epitopes along glycosaminoglycan
chains (gifts from Dr Bruce Caterson, Cardiff, Wales);
acid and basic Fuchsine (Chroma, Stuttgart-Untertu¨rkheim,
Germany); bFGF (Gibco BRL-Research, Basel,
Switzerland); bovine serum albumin (Serva Feinbio-
chemica GmbH, Heidelberg, Germany); bovine thrombin
(Immuno, Vienna, Austria); chondroitinase AC (Sigma
Chemical Company, St. Louis, MD, U.S.A.); fast green
(Fluka, Buchs, Switzerland); gluataraldehyde (Merck,
Darmstadt, Germany); fibrinogen (purified in our laboratory
from bovine or Goettingen miniature pig blood); gelatine
(Gelfoam®, Upjohn Company, Kalamazoo, U.S.A.); IGF-1
(Sigma-Aldrich, Buchs, Switzerland); horseradish-
peroxidase-conjugated goat-anti-mouse IgG 3-amino-9-
ethyl-carbazole (AEC-Tablets) (Sigma, Saint Louis,
U.S.A.); Mayer’s hematoxylin (Fluka, Buchs, Switzerland);
methyl methacrylate (Merck-Schuchardt, Hohenbrunn,
Germany); sodium cacodylate (Merck-Schuchardt,
Hohenbrunn, Germany); Tissue Tek® (Miles, Elkhart, IN,
U.S.A.); Toluidine Blue O (Merck, Darmstadt, Germany);
TGF-1 (R+D Systems, Minneapolis, MN, U.S.A.); xylene
(Merck-Schuchardt, Hohenbrunn, Germany).zone in adjacent native cartilage—transformed more
frequently than did more superficial ones—corresponding
to the level of the tangential zone in adjacent native
cartilage.
The histochemical staining for proteoglycans within
repair tissue varied considerably in intensity (see Table III).
Most sections manifested a degree intermediate between
that evinced in fibrous connective tissue (0) and normal
articular cartilage matrix (+ + +). Immunohistochemical
analyses of selected defects confirmed these findings, and
further revealed that some of the cartilage-specific epitopes
(i.e. the hyaluronic-acid-binding region for proteoglycans,
type II collagen fibrils, cartilage oligomeric matrix protein
and chondrotin-sulfate-specific sites for proteoglycan-
glycosaminoglycan chains) were indeed expressed in this
repair tissue (Fig. 3). But epitopes for fibrillar type I collagen
were also present, and these persisted throughout the
entire follow-up course. Polarization microscopy disclosed
collagen fibrils to be more isotropically organized than in
normal articular cartilage [Fig. 2].
Chondrocyte-like cells in the repair tissue did not adopt
the perfect anisotropic pattern of organization manifested in
normal articular cartilage, but a structural differentiation
gradient was nonetheless apparent: cells closest to the
defect surface tended to be more spindle-like than those in
deeper regions [see Fig. 1(C)]. The latter were distributed
more isotropically, and were usually present at higher
numerical densities, than in normal articular cartilage,
although this was not always the case [see Fig. 1(H)]. Albeit
so, they tended to adopt the size and shape characteristics
of cells in the physiological hypertrophic zone, and they
retained these conformations up to the end of the 1-year
observation period. Repair and native tissue compartments
were generally well integrated [Fig. 1(D)–(H); Fig. 2; Fig. 3],
although clefts were apparent in some locations [Fig. 1(C)].
Polarization microscopy confirmed the existence of good
tissue integration in cleft-free regions [Fig. 2(B)].
During the course of its polymerization, clotting and
stabilization, fibrin typically retracts.24,25 It was thus not
surprising that the matrices composed of this material
frequently, and to a variable degree, shrunk away from the
free defect surface. This phenomenon probably accounts
for the frequently concave contour of the repair-tissue
surface relative to that of the native articular cartilage [see
Fig. 1(C),(E)].
In the untreated group of miniature pigs (Group II in
Table I), a few mesenchymal-like cells were apparent along
the defect borders, and a limited degree of chondrocyte
proliferation was to be seen within vicinal native tissue,1 but
no repair tissue of any description was laid down at any
time during the 1-year follow-up period [Fig. 1(B)].
In defects treated with chondroitinase AC, free TGF-1
(4 ng/ml), a fibrin matrix and EMPTY liposomes (Group III
in Table I), a mesenchymal type of repair tissue was laid
down, as previously reported.1 There was no evidence of
transformation into cartilage-like tissue. Hence, liposomes,
per se, do not have any differentiation activity.
In defects treated first with chondroitinase AC and then
with an EMPTY fibrin matrix (Group IV in Table I), the clots
were sparsely populated with mesenchymal-like cells,
which had partially remodeled the fibrin and in its place had
laid down a tenuous mesenchymal-like connective tissue.1
Defects that received a gelatine matrix (Group V in
Table I) or a gelatine fibrin-copolymer (Group VI in Table I),
but in all other respects were treated similarly to the
experimental group of animals, were filled with a cartilage-
like repair tissue which was indistinguishable from that laidTable II
Degree of cell (tissue) differentiation in experimental defects
Degree of transformation
within sections
2 months 6 months 12 months
<25% 4% 20% 5%
26%–50% 16% 21% 10%
51%–75% 32% 24% 31%
>75% 48% 35% 54%
Number of sections analyzed 105 153 163
Number of defects analyzed 38 54 55Results
The repair tissue formed in the experimental group of
animals (Group I in Table I) bore a close resemblance to
cartilage [Fig. 1(C)–(H); Fig. 2]: cells manifested a
chondrocyte-like phenotype and were embedded within a
matrix which evinced the histochemical staining charac-
teristics of cartilage. As may be seen from Table II, the
degree of cell (tissue) differentiation was variable; but by
12 months, tissue within 54% of the defects had undergone
transformation to the extent of 75% or more. Temporal
differences in the percentage of defects manifesting a given
degree of tissue transformation probably reflect a broad
range of variation in the result achieved (which is typical for
cartilage repair studies) rather than de- and redifferentiation
effects. Detailed morphological analyses revealed that
deeper regions—corresponding to the level of the radial
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fibrin-specific effect. Substitution of miniature-pig-derived
fibrinogen for bovine-derived fibrinogen (Group X in Table I)
in the experimental protocol did not influence the repair
result.
When free IGF-1 (Group VII in Table I) or free bFGF
(Group VIII) were substituted for free TGF-1 in the exper-
imental protocol, essentially the same repair response was
elicited in each case, with the exception that the cellularityof the cartilage-like tissue formed in these substitute cases
was somewhat lower than in the presence of free TGF-1.
Omission of free TGF-1 from the experimental protocol
(Group IX in Table I) yielded a repair result that differed
from that elicited in its presence in only one respect: the
cellularity of the cartilage-like tissue formed was somewhat
lower.Table III
Histochemical staining for proteoglycans in the cartilage-like
repair-tissue matrix of experimental defects
Staining grade 2 months 6 months 12 months
0 36% 36% 23%
+ 37% 54% 36%
+ + 21% 9% 29%
+ + + 6% 1% 12%
Number of sections analyzed 105 153 163
Number of defects analyzed 38 54 55
0: Intensity corresponds to that of fibrous connective tissue.
+ + +: Intensity corresponds to that of native articular cartilage.Fig. 2. Polarization light micrographs of knee-joint articular cartilage in mature Goettingen miniature pigs. (A), (B) Superficial defects 2
months after instigation of the treatment and staining protocols described in the legend to Fig. 1, then visualized by polarization microscopy.
Polarized light signals (P) are identifiable; they are indicative of an anisotropic distribution of collagen fibrils in the native cartilage tissue. By
contrast, repair tissue appears pale and homogenously gray-blue; this is suggestive of its collagen fibrils being isotropically arranged. That
repair and native tissue are well integrated is evidenced by the absence of a distinct border (DB) between the two. D: defect. CC: calcified
cartilage; SCB: subchondral bone. Bars (A), (B)=100 m; final magnifications (A), (B)= ×66.Fig. 1. Light micrographs of knee-joint articular cartilage in mature Goettingen miniature pigs. (A) Normal articular cartilage tissue (AC)
together with the underlying layers of calcified cartilage (CC) and subchondral bone (SCB). (B) Untreated (control) defect (D) 12 months after
its creation. A few mesenchymal-like cells (MC) are to be seen along the lesion borders but no repair tissue of any description has been laid
down. AC: articular cartilage; CC: calcified cartilage; SCB: subchondral bone. (C), (D) Superficial defects 2 months after treatment with
chondroitinase AC and application of a fibrin matrix containing both free (4 ng/ml) and liposome-encapsulated (600 ng/ml) TGF-1. Each
defect (D) is filled with repair tissue which has a cartilage-like appearance. Cells have undergone transformation into chondrocyte-like ones,
but are more isotropically distributed and present at a higher numerical density than those within the surrounding native tissue. A gradient
in cell size and shape is nonetheless apparent, chondrocytes in superficial regions being small and spindle-like (SLC), those in deeper ones
being larger and having an oblate spheroid form (OSC). Chondrocyte-like cells have laid down a matrix which stains somewhat less
homogeneously than that of native tissue, which circumstance indicates that it is not truely hyaline, but rather fibrous, in nature. At the defect
borders (DB), repair and native tissue are well integrated except at the upper-right and lower-left corners (CL) in (C). (E), (F) Superficial
defects (D) 6 months after the treatment described above. Contiguity between repair and native tissue (DB) has been maintained, but
chondrocytes are still more isotropically distributed and present at a higher numerical density than those in the vicinal native cartilage. These
two examples illustrate well the paler-than-normal staining properties of the intercellular matrix, this circumstance being indicative of its lower
progeoglycan content. (G), (H) Superficial defects (D) 12 months after instigation of the treatment protocol described above. The situation
is comparable to that manifested at 6 months, i.e. tissue has undergone no further differentiation during the interim. However, the very
stability of repair tissue at this stage is by no means a trivial circumstance. A-H: 120 m-thick polished saw-cuts, surface-stained with
McNeil’s tetrachrome/Toluidine Blue O/basic Fuchsine. Bars=100 m (A, C–H) and 200 m (B); final magnifications= ×80 (A, C–H) and
×35 (B).Discussion
In the forerunner1 to the present investigation, we
demonstrated that when partial-thickness defects within
mature articular cartilage are filled with a space-defining
fibrin matrix containing a free chemotactic/mitogenic factor,
cells for the repair process can be stimulated to migrate
from the synovium, to populate the matrix scaffold, and
therein to undertake its remodeling into a primitive type of
connective tissue. Although this scar-like tissue endured, it
failed to transform into cartilage. It was the aim of the
present investigation to elicit this tissue transformation by
introducing a liposome-encapsulated chondrogenic differ-
entiation factor into the fibrin matrix along with the free
chemotactic/mitogenic one. We hoped that this tissue
28 E. B. Hunziker: Partial-thickness defects in adult articular cartilageFig. 3.
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matrix remodeling was well under way, thereby optimizing
the differentiation of primitive into cartilage-like tissue. Our
treatment principle thus aimed at the sequential stimulation
of articular cartilage’s intrinsic repair potential by use of
appropriate growth factors delivered at the critical junc-
tures. On the basis of this rationale, we were able to induce
the repair of partial-thickness defects in mature articular
cartilage. The beauty of such a treatment principle is that it
culls the tissue’s natural resources, thereby obviating the
need for cell or tissue transplantation (with the potential risk
of inducing adverse immunological reactions), and can be
instigated during a single surgical intervention.
The histological, histochemical, immunohistochemical
and polarization microscopic characterization of the repair
tissue clearly revealed it to be cartilage-like in nature. All
the functionally-important cartilage matrix components26–31
were present in appreciable quantities. That the repair
tissue endured throughout the course of the entire
follow-up period, i.e. 1 year, is strongly supportive of its
being compositionally stable. However, the persistence of
type I collagen, a component not typically present in hyaline
cartilage matrix, as well as the relatively low proteoglycan
content, suggest that its composition, and hence also its
functional competence, were not optimal. Similar problems
have been experienced hitherto in all types of cartilage-
repair concepts (for reviews, see10,32–35). It remains to be
clarified whether the type I collagen encountered is indeed
merely a remnant of the scar-like tissue initially laid down or
whether this material continues to be produced even after
differentiation processes have begun (as occurs in fibrous
cartilage). Given the long half-life of fibrillar collagen in
skeletal tissues,36–38 the former possibility seems likely.
Whatever the case, the persistence of type I collagen
will undoubtedly influence the properties of the repair
tissue formed. Mechanical testing of such small lesions as
those described here is, however, not practicable; a much
larger superficial-defect model would be required for such
purposes.
The presence of cartilage-specific matrix components
(such as cartilage oligomeric matrix protein,31 type II
collagen28–30 and aggrecan30) in the repair tissue argues
favorably for a relatively high degree of tissue transforma-
tion, as does the existence of chondrocyte-like cells mani-
festing different degrees of morphological differentiation.
The predominance of spindle-like cells in superficial
regions and of large hypertrophic ones in deeper zones
accords well with the physiological situation.39,40 A clear-
cut gradient and perfectly columnar arrangement of cells
was, however, not achieved, and cellularity was generally
too high. Further improvements in the architectural result
could possibly be achieved by the introduction of sub-
stances known to influence cartilage maintenance (e.g.
insulin-like growth factor II).
One of the great assets of our proposed treatment
protocol is that cells for the repair process are recruited
from joint-specific tissue sources.1 During fetal develop-ment, joints in different topographical regions of the
skeleton adopt the shapes and structures commensurate
with their biomechanical and biochemical needs, which can
vary considerably. Since synovial-joint tissues differentiate
from locally-specific mesenchymal cells, the recruitment of
these latter for the purposes of local repair would appear to
be ideal.41–44
Interfacial integration between repair tissue and native
cartilage was generally good, as revealed by polarization
microscopy. This is an aspect of considerable practical
importance, since any clefts existing in the interfacial
region represent potential sites for tissue degradation by
proteases present within the synovial fluid.45,46
The physiological effects and biological activities of
differentiation factors are influenced not only by the cell
types involved, and their microenvironment, but also by the
concentrations of these agents.47 In vitro, TGF-1 has
been shown to act in the capacity of a chemotactic and/or
mitogenic agent at low activities (0.1–10 ng/ml), whereas at
higher ones (>100 ng/ml), these effects are reversed and
chemotaxis may even be inhibited.12,48–54 Moreover, at
these high activities, this substance is known to promote
tissue transformation or differentiation.12,15,48,50 Hence,
the precise control of growth-factor concentration in
clinically-applied systems is of fundamental importance.
In a preliminary investigation (data not presented),
TGF-1 was shown to act in its chondrogenic differentiation
capacity over the range 100–1500 ng/ml, with no adverse
consequences. However, there is a limit to which one can
go in this respect, since the leakage of very high concen-
trations into the joint cavity could lead to synovitis, pannus
or osteophyte formation and cartilage degradation.17,18,55
For this reason, use of the minimal effective concentration
is advisable. To be on the safe side, we chose one of
600 ng/ml.
The mechanism whereby the encapsulated differentia-
tion factor is released in vivo can only be speculated upon
at present. One possibility is that the liposomes are them-
selves phagocytozed by the synovial cells, within which
they are degraded and the TGF-1 thereby liberated,
perhaps to act via an intracellular signaling pathway (as
reported for bFGF56). Alternatively, liposomes could be
degraded within the extracellular space, and the released
TGF-1 induce cell differentiation processes via plasma-
lemmal receptors.57,58 Both possibilities are indeed feas-
ible, since TGF-1 is known to be capable of stimulating
cell activities from both intra- and extracellular sites.57–59
The important point to bear in mind is that the
concentration-specific effects of TGF-1 as either a
mitogenic/chemotactic factor (at low activity) or a differ-
entiation one (at high activity) require the sequential appli-
cation of this substance (at the required activity levels) in
order to induce the desired effects at the appropriate points
in time. The release of liposome-encapsulated TGF-1 at
a stage when synovial cells have already invaded the
fibrin matrix and begun to remodel it, represents anFig. 3. Light micrographs of immunohistochemically-stained repair tissue in Goettingen miniature pigs, 2 months after instigation of the
treatment protocol described in the legend to Fig. 1. (A), (B) Controls for polyclonal (A) and monoclonal (B) antibodies, using dansylated and
chrome-pure epitopes, respectively. Both sections register negative after the alkaline phosphatase reaction (absence of brown staining), in
native (N) as well as in repair (R) tissue areas. (C)–(H) Both repair (R) and native (N) cartilage matrix areas react positively (presence of
brown staining) and similarly to antibodies against glycosaminoglycans [3B3-antibody (C) and 9-A-2 antibody (E)], type II collagen (D), the
hyaluronic-acid-binding region (G) and cartilage oligomeric matrix protein (H). Native articular cartilage matrix registers negative to the
antibody against type I collagen (F), whereas repair tissue matrix manifests a weak positive reaction. Arrow heads=defect borders.
Bars=100 m (A) and 50 m (B)–(H).
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cells themselves.
Other sequestering systems are available (e.g. gelatine-
microspheres,60 polylactic-glycoside capsules61 and fibril-
associated delivery62–64), and any of these could, in
principle, be considered as alternatives to the liposome-
encapsulation mode adopted by ourselves.
The synovial cells involved in this repair process appear
to have a very limited perception of space, and an artificial
matrix is thus required as a guide to define the defect void.1
Moreover, the porosity of this matrix needs to be such that
these cells can grow into and populate it.65 A biodegradable
material (such as fibrin, gelatine or collagen, or copolymers
of these) is preferable, since the mechanical and chemical
properties of non-biodegradable ones change with time,
and some degradation- or release products generated over
longer periods may have local toxic effects. The fibrin
matrix used by ourselves served as a starting point for
establishing the principles of repair induction in partial-
thickness articular cartilage defects; but it is clearly not the
ideal choice for clinical purposes, owing to the clot-
retraction problem which leads to incomplete filling of the
defect space.
Variations in the degree to which tissue transformation
takes place stem not only from problems with the matrix,
but also from those associated with the preparation of
liposomes. The method employed22 yields particles span-
ning a fairly broad size-range [from less than 1 m up to
15 m in diameter (determined by electron microscopy;
data not presented)]. If we could secure a more uniform
size distribution, as well as improve the mixing process with
the matrix (to obtain a more even distribution of particles),
then two sources of variability would be eliminated. We
have, in fact, recently tested a population of polylactate
microspheres for TGF-1 incorporation and delivery, which
has a very homogeneous particle size (<1 m in diameter).
Preliminary testing with such suspensions has yielded
reproducibly complete tissue-transformation results (data
not presented).
Our system is clearly not yet ready for clinical use; but
then, it was not the purpose of this study to realize this end,
but rather to delineate the working principles of a protocol
whereby healing of partial-thickness defects in mature
articular cartilage could be induced by culling the tissue’s
own natural resources. Indeed, the results achieved at this
stage are far better than our most sanguine expectations.ment from the synovial membrane. J Bone Joint Surg
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